CN112007089A - A Chinese medicinal oral liquid for treating nephritis - Google Patents
A Chinese medicinal oral liquid for treating nephritis Download PDFInfo
- Publication number
- CN112007089A CN112007089A CN202011041570.7A CN202011041570A CN112007089A CN 112007089 A CN112007089 A CN 112007089A CN 202011041570 A CN202011041570 A CN 202011041570A CN 112007089 A CN112007089 A CN 112007089A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- salvia miltiorrhiza
- oral liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine oral liquid for treating nephritis, which is prepared from the following raw materials: astragalus root, epimedium, cherokee rose root, scandent hop, eclipta, clerodendranthus spicatus, bittersweet herb and salvia miltiorrhiza. Preferably, the material is prepared from the following raw materials in parts by weight: 10-20 parts of astragalus membranaceus, 5-15 parts of herba epimedii, 5-10 parts of cherokee rose roots, 5-10 parts of scandent hop, 5-10 parts of eclipta alba, 5-15 parts of folium orthosiphoni, 5-15 parts of solanum lyratum and 5-10 parts of salvia miltiorrhiza. The invention has the effects of promoting blood circulation, removing blood stasis, diminishing inflammation, relieving pain, separating clear, eliminating turbid, improving circulation, nourishing kidney yin, invigorating kidney yang, improving kidney function and improving immunity of organisms, can effectively treat chronic nephritis, and has the advantages of quick curative effect, no toxic or side effect and convenient administration.
Description
Technical Field
The invention relates to the field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine oral liquid for treating nephritis.
Background
Glomerulonephritis, also known as nephritic syndrome (nephritis for short), is a common kidney disease, which is a disease occurring in bilateral renal glomeruli due to various reasons and clinically manifested as a group of syndromes. Glomerulonephritis is commonly expressed as (and may not occur simultaneously): edema, proteinuria, hematuria, hypertension, decreased or no urine volume, and normal or decreased renal function.
At present, in the treatment of nephritis, western medicines are mainly taken and are assisted by traditional Chinese medicine treatment, and the western medicines have the characteristic of quick response, but have the problems of large side effect, easy damage to the liver, temporary treatment and non-permanent treatment, and easy generation of drug resistance after long-term taking; various traditional Chinese medicine combination preparations for traditional Chinese medicine treatment generally have the conditions of slow curative effect, low effective rate, troublesome decoction and taking, unpleasant smell, low absorption rate and more pain when being taken by patients.
Disclosure of Invention
In order to solve the problems, the invention provides the traditional Chinese medicine oral liquid for treating nephritis, which has the characteristics of quick curative effect, high effective rate and convenient taking.
In order to achieve the purpose, the invention adopts the technical scheme that:
a traditional Chinese medicine oral liquid for treating nephritis is prepared from the following raw materials:
astragalus root, epimedium, cherokee rose root, scandent hop, eclipta, clerodendranthus spicatus, bittersweet herb and salvia miltiorrhiza.
Preferably, the material is prepared from the following raw materials in parts by weight:
10-20 parts of astragalus membranaceus, 5-15 parts of herba epimedii, 5-10 parts of cherokee rose roots, 5-10 parts of scandent hop, 5-10 parts of eclipta alba, 5-15 parts of folium orthosiphoni, 5-15 parts of solanum lyratum and 5-10 parts of salvia miltiorrhiza.
Preferably, the material is prepared from the following raw materials in parts by weight:
10 parts of astragalus, 5 parts of herba epimedii, 5 parts of cherokee rose root, 5 parts of scandent hop, 5 parts of eclipta alba, 5 parts of folium orthosiphoni, 5 parts of solanum lyratum and 5 parts of salvia miltiorrhiza.
Preferably, the material is prepared from the following raw materials in parts by weight:
20 parts of astragalus membranaceus, 15 parts of herba epimedii, 10 parts of cherokee rose roots, 10 parts of scandent hop, 10 parts of eclipta alba, 15 parts of folium orthosiphoni, 15 parts of solanum lyratum and 10 parts of salvia miltiorrhiza.
Preferably, the material is prepared from the following raw materials in parts by weight:
15 parts of astragalus, 10 parts of herba epimedii, 7.5 parts of cherokee rose root, 7.5 parts of scandent hop, 7.5 parts of eclipta alba, 10 parts of clerodendranthus spicatus, 10 parts of solanum dulcamara and 7.5 parts of salvia miltiorrhiza.
Further, when the oral liquid is prepared, the weighed astragalus, the herba epimedii, the cherokee rose root, the humulus scandens, the eclipta alba, the clerodendroa cyrtophyllum, the solanum dulcamara and the salvia miltiorrhiza are respectively cleaned and drained, cut into sections/pieces, mixed, crushed into 200 meshes in an ultramicro crusher, sieved, placed in an enzymolysis tank, added with 2-3% of aspergillus niger, 2-6% of trichoderma and 2-3% of saccharomycetes by mass percentage, subjected to enzymolysis for 5-6 hours at 30-50 ℃, filtered, added with 3-5% of flavourzyme, subjected to enzymolysis for 3-4 hours at 30-50 ℃, rapidly frozen and naturally thawed, so that starch in the extract is aged and precipitated; collecting supernatant, centrifuging the rest part, collecting the centrifuged liquid, mixing with the supernatant, inactivating enzyme, canning, and sterilizing.
The invention has the effects of promoting blood circulation, removing blood stasis, diminishing inflammation, relieving pain, separating clear, eliminating turbid, improving circulation, nourishing kidney yin, invigorating kidney yang, improving kidney function and improving immunity of organisms, can effectively treat chronic nephritis, and has the advantages of quick curative effect, no toxic or side effect, convenient administration and high absorption rate of active ingredients of the medicine.
Detailed Description
The present invention will be described in detail with reference to specific examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that variations and modifications can be made by persons skilled in the art without departing from the spirit of the invention. All falling within the scope of the present invention.
Example 1
S1, weighing the following components in parts by weight: 10 parts of astragalus, 5 parts of herba epimedii, 5 parts of cherokee rose root, 5 parts of scandent hop, 5 parts of eclipta alba, 5 parts of folium orthosiphoni, 5 parts of solanum lyratum and 5 parts of salvia miltiorrhiza;
s2, respectively cleaning and draining radix astragali, herba Epimedii, radix Rosae Laevigatae, herba Humuli Scandentis, Ecliptae herba, herba Clerodendranthi Spicati, herba Solani Lyrati and Saviae Miltiorrhizae radix, cutting into segments/pieces, mixing, pulverizing into 200 mesh powder in an ultramicro pulverizer, and sieving to obtain Chinese medicinal powder;
s3, placing the obtained traditional Chinese medicine powder into an enzymolysis tank, adding 2% of Aspergillus niger, 4% of Trichoderma and 2% of microzyme by mass percentage, carrying out enzymolysis for 5-6 h at 30-50 ℃, filtering, adding 3% of flavourzyme, and carrying out enzymolysis for 3-4 h at 30-50 ℃ to obtain an enzymolysis solution;
s4, quickly freezing the obtained enzymolysis liquid, and naturally thawing to age and precipitate starch in the extract; collecting supernatant, centrifuging the rest part, collecting the centrifuged liquid, mixing with the supernatant, inactivating enzyme, canning, and sterilizing.
Example 2
S1, weighing the following components in parts by weight: 20 parts of astragalus membranaceus, 15 parts of herba epimedii, 10 parts of cherokee rose roots, 10 parts of scandent hop, 10 parts of eclipta alba, 15 parts of folium orthosiphoni, 15 parts of solanum lyratum and 10 parts of salvia miltiorrhiza;
s2, respectively cleaning and draining radix astragali, herba Epimedii, radix Rosae Laevigatae, herba Humuli Scandentis, Ecliptae herba, herba Clerodendranthi Spicati, herba Solani Lyrati and Saviae Miltiorrhizae radix, cutting into segments/pieces, mixing, pulverizing into 200 mesh powder in an ultramicro pulverizer, and sieving to obtain Chinese medicinal powder;
s3, placing the obtained traditional Chinese medicine powder into an enzymolysis tank, adding 3% of Aspergillus niger, 6% of Trichoderma and 3% of microzyme by mass percentage, carrying out enzymolysis for 5-6 h at 30-50 ℃, filtering, adding 5% of flavourzyme, and carrying out enzymolysis for 3-4 h at 30-50 ℃ to obtain an enzymolysis solution;
s4, quickly freezing the obtained enzymolysis liquid, and naturally thawing to age and precipitate starch in the extract; collecting supernatant, centrifuging the rest part, collecting the centrifuged liquid, mixing with the supernatant, inactivating enzyme, canning, and sterilizing.
Example 3
S1, weighing the following components in parts by weight: 15 parts of astragalus, 10 parts of herba epimedii, 7.5 parts of cherokee rose root, 7.5 parts of scandent hop, 7.5 parts of eclipta alba, 10 parts of clerodendranthus spicatus, 10 parts of solanum dulcamara and 7.5 parts of salvia miltiorrhiza;
s2, respectively cleaning and draining radix astragali, herba Epimedii, radix Rosae Laevigatae, herba Humuli Scandentis, Ecliptae herba, herba Clerodendranthi Spicati, herba Solani Lyrati and Saviae Miltiorrhizae radix, cutting into segments/pieces, mixing, pulverizing into 200 mesh powder in an ultramicro pulverizer, and sieving to obtain Chinese medicinal powder;
s3, placing the obtained traditional Chinese medicine powder into an enzymolysis tank, adding 2.5% of Aspergillus niger, 5% of Trichoderma and 2.5% of microzyme by mass percentage, carrying out enzymolysis for 5-6 h at 30-50 ℃, filtering, adding 4% of flavourzyme, and carrying out enzymolysis for 3-4 h at 30-50 ℃ to obtain an enzymolysis liquid;
s4, quickly freezing the obtained enzymolysis liquid, and naturally thawing to age and precipitate starch in the extract; collecting supernatant, centrifuging the rest part, collecting the centrifuged liquid, mixing with the supernatant, inactivating enzyme, canning, and sterilizing.
The taking method comprises the following steps: the medicine is taken 2 times a day, 5-15 ml each time (the weight and age of a patient are increased and decreased as appropriate), one treatment course is 30 days, and salt and spicy taste are avoided during the taking period.
The prescription is adopted to clinically treat 86 glomerulonephritis patients, and the results are as follows: 51 cases are cured clinically, 29 cases are obviously effective, 6 cases are effective, 0 case is ineffective, and the total effective rate is 100%.
The method is adopted to clinically treat 62 patients with pyelonephritis, and the results are as follows: 32 cases are cured clinically, the obvious effect is 27, the effective cases are 3, the ineffective cases are 0, and the total effective rate is 100 percent.
The foregoing description of specific embodiments of the present invention has been presented. It is to be understood that the present invention is not limited to the specific embodiments described above, and that various changes or modifications may be made by one skilled in the art within the scope of the appended claims without departing from the spirit of the invention. The embodiments and features of the embodiments of the present application may be combined with each other arbitrarily without conflict.
Claims (6)
1. A traditional Chinese medicine oral liquid for treating nephritis is characterized in that: the preparation method is characterized by comprising the following steps:
astragalus root, epimedium, cherokee rose root, scandent hop, eclipta, clerodendranthus spicatus, bittersweet herb and salvia miltiorrhiza.
2. The traditional Chinese medicine oral liquid for treating nephritis according to claim 1, characterized in that: the feed is prepared from the following raw materials in parts by weight:
10-20 parts of astragalus membranaceus, 5-15 parts of herba epimedii, 5-10 parts of cherokee rose roots, 5-10 parts of scandent hop, 5-10 parts of eclipta alba, 5-15 parts of folium orthosiphoni, 5-15 parts of solanum lyratum and 5-10 parts of salvia miltiorrhiza.
3. The traditional Chinese medicine oral liquid for treating nephritis according to claim 2, characterized in that: the feed is prepared from the following raw materials in parts by weight:
10 parts of astragalus, 5 parts of herba epimedii, 5 parts of cherokee rose root, 5 parts of scandent hop, 5 parts of eclipta alba, 5 parts of folium orthosiphoni, 5 parts of solanum lyratum and 5 parts of salvia miltiorrhiza.
4. The traditional Chinese medicine oral liquid for treating nephritis according to claim 2, characterized in that: the feed is prepared from the following raw materials in parts by weight:
20 parts of astragalus membranaceus, 15 parts of herba epimedii, 10 parts of cherokee rose roots, 10 parts of scandent hop, 10 parts of eclipta alba, 15 parts of folium orthosiphoni, 15 parts of solanum lyratum and 10 parts of salvia miltiorrhiza.
5. The traditional Chinese medicine oral liquid for treating nephritis according to claim 2, characterized in that: the feed is prepared from the following raw materials in parts by weight:
15 parts of astragalus, 10 parts of herba epimedii, 7.5 parts of cherokee rose root, 7.5 parts of scandent hop, 7.5 parts of eclipta alba, 10 parts of clerodendranthus spicatus, 10 parts of solanum dulcamara and 7.5 parts of salvia miltiorrhiza.
6. The traditional Chinese medicine oral liquid for treating nephritis according to claim 1, characterized in that: the preparation method comprises the steps of respectively cleaning and draining the weighed astragalus, herba epimedii, cherokee rose root, scandent hop, eclipta alba, clerodendranthus spicatus, solanum dulcamara and salvia miltiorrhiza, cutting into sections/pieces, mixing, crushing into 200 meshes in an ultramicro crusher, sieving, placing in an enzymolysis tank, adding 2-3% of aspergillus niger, 2-6% of trichoderma and 2-3% of saccharomycetes according to the mass percentage, carrying out enzymolysis for 5-6 h at 30-50 ℃, filtering, adding 3-5% of flavourzyme, carrying out enzymolysis for 3-4 h at 30-50 ℃, quickly freezing the obtained enzymolysis liquid, and naturally thawing to age and precipitate starch in the extract; collecting supernatant, centrifuging the rest part, collecting the centrifuged liquid, mixing with the supernatant, inactivating enzyme, canning, and sterilizing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011041570.7A CN112007089A (en) | 2020-09-28 | 2020-09-28 | A Chinese medicinal oral liquid for treating nephritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011041570.7A CN112007089A (en) | 2020-09-28 | 2020-09-28 | A Chinese medicinal oral liquid for treating nephritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112007089A true CN112007089A (en) | 2020-12-01 |
Family
ID=73528220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011041570.7A Pending CN112007089A (en) | 2020-09-28 | 2020-09-28 | A Chinese medicinal oral liquid for treating nephritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112007089A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1091968A (en) * | 1993-03-06 | 1994-09-14 | 管益君 | A kind of medicine and preparation method thereof |
| CN107258995A (en) * | 2017-05-11 | 2017-10-20 | 张晓光 | A kind of preparation method for reducing prostatitis drink |
| CN108403783A (en) * | 2018-04-19 | 2018-08-17 | 南方医科大学 | A kind of humulus green pepper oral solution and preparation method thereof and detection method |
-
2020
- 2020-09-28 CN CN202011041570.7A patent/CN112007089A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1091968A (en) * | 1993-03-06 | 1994-09-14 | 管益君 | A kind of medicine and preparation method thereof |
| CN107258995A (en) * | 2017-05-11 | 2017-10-20 | 张晓光 | A kind of preparation method for reducing prostatitis drink |
| CN108403783A (en) * | 2018-04-19 | 2018-08-17 | 南方医科大学 | A kind of humulus green pepper oral solution and preparation method thereof and detection method |
Non-Patent Citations (9)
| Title |
|---|
| 张宁，等: "肾炎益气液对慢性肾炎病人血肌酐及其倒数的影响", 《中华中医药杂志》 * |
| 张永康，等: "原明忠治疗慢性肾小球肾炎的临证体会", 《中国中西医结合肾病杂志》 * |
| 殷紫，等: "抗肿瘤虎杖复方制剂工艺研究", 《科技视界》 * |
| 王兰: "清热解毒活血法治疗慢性肾盂肾炎临床小结", 《黑龙江中医药》 * |
| 章永红，等: "补气活血益肾利湿治疗慢性肾炎的临床与动物实验研究", 《中医杂志》 * |
| 谢建芬: "慢性肾小球肾炎的辨治体会", 《贵阳中医学院学报》 * |
| 韩晗，编著: "《微生物资源开发学》", 31 March 2018, 西南交通大学出版社 * |
| 高文远，主编: "《中药生物工程》", 31 January 2014, 上海科学技术出版社 * |
| 高菁，等: "辨证论治为主治疗肾病综合征100例", 《北京中医药大学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN107296772A (en) | A kind of skin care item containing holy basil extract and its preparation | |
| CN112675278A (en) | Composition for moistening lung to arrest cough and inhibiting lung inflammatory reaction and preparation method and application thereof | |
| CN107625828A (en) | A kind of health protection tea for auxiliary treatment chronic pharyngitis, preparation method and application | |
| CN104257816B (en) | A kind of composition for treating berloque dermatitis and preparation method thereof | |
| CN112007089A (en) | A Chinese medicinal oral liquid for treating nephritis | |
| CN100345571C (en) | Medication for treating necrosis of femoral head and preparation method | |
| CN103127272A (en) | Chinese medicinal preparation for treating breast disease and preparation method thereof | |
| CN100488543C (en) | Local externally applied itch stopping garlic liniments | |
| CN102614319B (en) | Medicinal composition for treating fracture healing | |
| CN112107605A (en) | Cynomorium songaricum extract and preparation process thereof | |
| CN105477597A (en) | Traditional Chinese medicinal composition for treating osteoidosteoma and preparation method of traditional Chinese medicinal composition | |
| CN105853768B (en) | Traditional Chinese medicine formula for treating rheumatoid arthritis and preparation method and application thereof | |
| CN101934046B (en) | Semifluid extract of deer foetus and preparation method thereof | |
| CN106983813B (en) | A pharmaceutical composition for treating lumbago and preparation method thereof | |
| CN105853866A (en) | Method for preparing Chinese herbal medicine composition for treating bedsore | |
| CN115531471B (en) | Composition for resisting African swine fever as well as preparation method and application thereof | |
| CN109106883A (en) | A kind of pharmaceutical composition for treating eczema | |
| CN103446369B (en) | Pharmaceutical composition for treating sudden deafness | |
| CN1075385C (en) | Medicine for treatment of piles and preparation method thereof | |
| CN111700977B (en) | Traditional Chinese medicine composition for promoting fracture healing and preparation method and application thereof | |
| CN110575506B (en) | Traditional Chinese medicine composition for treating lumbar disc herniation | |
| CN106853193A (en) | It is a kind of to treat Chinese medicine of rheumatoid arthritis and preparation method thereof | |
| CN1139572A (en) | Complex ant preparation for male sexual function promoting and preparation process | |
| CN105770552A (en) | Chinese herba preparation containing folium artemisiae argyi and used for treating prostatitis and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201201 |
|
| RJ01 | Rejection of invention patent application after publication |